Oblenio Bio raised a $62 million Series B to advance its autoimmune disease therapy.
- Amount
- $62M
- Stage
- Series B
- Announced
- 27 June 2026
- Lead
- Pfizer Ventures
- Other investors
- Deep Track Capital, GV, Aditum Bio
- Use of funds
- Initial clinical development of LBL-051, including first-in-human proof-of-concept study this year.
- Checked
- Amount and date checked against the press source